Key facts
- Notable investors include Monash University.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Fyton Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Fyton Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fyton Bio
Developer of antibody therapeutics designed to eliminate disease-causing immune cells in autoimmune and inflammatory conditions. The company offers therapies utilizing a GPCR-based rare epitope antibody discovery platform with mechanisms for precise immune cell deletion, enabling pharmaceutical companies and clinicians to access targeted therapies for autoimmune diseases, providing new treatment options aimed at achieving functional cures.
- Sector
- Healthcare
- HQ
- NJ
- Founded
- 2024
- Employees
- 2
- Ownership
- Privately Held (backing)
Fyton Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fyton Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fyton Bio in its N-PORT filings yet. We sweep new filings monthly.